Pipeline
Small Molecule Drug Conjugate (SMDC & ALDC)
First-in-class, Precision Guided Cancer Therapy, could replace the original drug and suitable to combine with immunotherapy.
Drug Name Payload/MOA/Target Indication Rights Development Stage
Pre-clinical IND Phase I Phase II Phase III
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
Tumor MicroEnvironment Activated Small Molecule Drug Conjugates (TMEA-ALDC & TMEA-SMDC)
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
QHL-108
(Legubicin)
Doxorubicin Soft Tissue Sarcoma Global
Lung Adenocarcinoma Global
Ovarian Cancer Global
QHL-236
(Legutaxel)
Paclitaxel Solid Tumor Global
Bladder Cancer Global
QHL-1618 DXd Solid Tumor Ex-Greater China
QHL-1231 AXL/VEGF/cMET Multikinase Inhibitor Solid Tumor Global
QHL-1031 TLR7/8 Agonist Solid Tumor Global
QHL-1306 TLR7/8-DXd Solid Tumor Global
QHL-1848 Eribulin Solid Tumor Global
QHL-1726 PAN-RASi Solid Tumor Global
QHL-1735 PAN-RASi-DXd Solid Tumor Global
QHL-1207 DOX-TLR7/8 Solid Tumor Global
QHL-506 PARPi Solid Tumor Global
QHL-339 Platinum Solid Tumor Global
   Registrational Clinical Trial
Biologics Conjugate
Best-In-Class Biologics including conjugate cytokines, antibodies, fusion proteins, and ADCs to create new generation drugs.
Drug Name Payload/MOA/Target Indication Rights Development Stage
Pre-clinical IND Phase I Phase II Phase III
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
Tumor MicroEnvironment Activated Antibodies (TMEAbody & TMEA-ICE), Cytokines and Fusion Proteins (TMEAkine)
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
IMD-101 IL-2 (Mask WT IL-2) Solid Tumor Global
IMD-303 CTLA-4 (Mask CTLA-4) Solid Tumor Global
IMD-1005 CD47 (Mask CD47) Solid Tumor Global
IMD-2816 CDH17-CD3 (Mask CD3) Solid Tumor Global
IMD-1112 CLDN18.2-CD3 (Mask CD3) Solid Tumor Global
IMD-1618 CLDN6-CD3 (Mask CD3) Solid Tumor Global
IMD-2032 PD1-IL2 (Mask WT IL-2) Solid Tumor Global
IMD-3525 PMSA-CD3 (Mask CD3) Solid Tumor Global
IMD-2035 PD1-VEGFR-IL2 (Mask WT IL-2) Solid Tumor Global
IMD-923 DLL3-SSTR2-CD3 (Mask CD3) Solid Tumor Global
Tumor MicroEnvironment Activated ADCs (TMEA-ADC)
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
IMD-1628 CLND6-TMEAlinker-DXd Solid Tumor Global
IMD-2109 PDL1-TMEAlinker-TLR7/8 Solid Tumor Global
IMD-2358 ROR1-TMEAlinker-DXd-TLR7/8 Solid Tumor Global
IMD-2113 EGFR-TROP2-TMEAlinker-DXd-TLR7/8 Solid Tumor Global
IMD-2128 EGFR-cMET-TMEAlinker-Eribulin Solid Tumor Global
IMD-2329 DLL3-B7H3-TMEAlinker-DXd-TLR7/8 Solid Tumor Global
IMD-526 HER2-TMEAlinker-DXd-TLR7/8 Solid Tumor Global
IMD-532 HER2-TMEAlinker-Eribulin Solid Tumor Global
IMD-2126 PDL1-TMEAlinker-DXd-TLR7/8 Solid Tumor Global
IMD-2369 ROR1-TMEAlinker-Eribulin Solid Tumor Global
IMD-2136 EGFR-cMET-TMEAlinker-DOX Solid Tumor Global
IMD-3623 DLL3-SEZ6-ADC Solid Tumor Global
IMD-3731 Nectin-4-ADC Solid Tumor Global
IMD-3857 ITGB6-ADC Solid Tumor Global
IMD-2206 LY6G6D (ADC) Solid Tumor Global
Partners
Product (Partners) Molecule Rights Development Stage
Pre-clinical IND Phase I Phase II Phase III
Product (Partners) Molecule Rights Pre-clinical IND Phase I Phase II Phase III
Product (Partners) Molecule Rights Pre-clinical IND Phase I Phase II Phase III

I-MAB

Confidential Global
Confidential

Anglikang Pharmaceutical

QHL-1618 TMEA-DXd Greater China

Partner

TMEAbody Platform Global

Partner

TMEA-SMDC Platform Global
* Partners and collaborative details are not fully disclosed due to commercial sensitivity